Erudio Healtherudio.com
Sponsor
HUTCHMED trials: what clinicians said in public
An HCP commentary report on 1 clinical trial sponsored by HUTCHMED: SANOVO. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 3 more trials with public commentary and no report yet.
Listed by lead sponsor as registered on ClinicalTrials.gov (Hutchison Medipharma Limited; Hutchmed). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| SANOVO NCT05009836 · Hutchmed | first-line EGFRm+/MET+ locally advanced or metastatic NSCLC | Phase 3 | 97 | 44 | Focused | Nov 13, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| FRESCO-2 NCT04322539 · Hutchison Medipharma Limited DeepView → | refractory metastatic colorectal cancer | Phase 3 | Deep | View | |||
| SACHI NCT05015608 · Hutchison Medipharma Limited DeepView → | advanced EGFR mutation-positive, MET-amplified non-small-cell lung cancer | Phase 3 | Deep | View | |||
| NCT02897479 NCT02897479 · Hutchison Medipharma Limited FocusedView → | Not given | Phase 2 | Focused | View | |||